Supernus Pharmaceuticals Inc (SUPN)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | 85,062 | 63,657 | 32,701 | -6,085 | 4,194 | 38,528 | 29,919 | 59,270 | 65,413 | 35,337 | 68,942 | 92,510 | 92,871 | 130,083 | 153,997 | 170,320 | 188,083 | 188,802 | 175,255 | 170,365 |
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | 0 | 0 | 400,382 | 379,252 | 374,788 | 370,383 | 366,038 | 361,751 | 357,521 | 353,349 | 349,232 |
| Total stockholders’ equity | US$ in thousands | 1,035,730 | 1,007,150 | 957,454 | 929,166 | 921,516 | 912,191 | 919,908 | 912,150 | 886,204 | 852,798 | 841,434 | 828,446 | 815,851 | 810,468 | 785,579 | 754,444 | 744,858 | 708,879 | 665,974 | 613,383 |
| Return on total capital | 8.21% | 6.32% | 3.42% | -0.65% | 0.46% | 4.22% | 3.25% | 6.50% | 7.38% | 4.14% | 8.19% | 7.53% | 7.77% | 10.98% | 13.32% | 15.20% | 17.00% | 17.70% | 17.19% | 17.70% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $85,062K ÷ ($—K + $1,035,730K)
= 8.21%
Supernus Pharmaceuticals Inc's return on total capital has displayed a fluctuating trend over the period from March 31, 2020, to December 31, 2024. The return on total capital started at a relatively high level of 17.70% in March 2020 and maintained a similar range until June 2021, signaling strong capital efficiency. However, there was a notable decline in the return on total capital from March 2021 to December 2021, dropping from 15.20% to 7.77%.
The downward trend continued into 2022, with return on total capital decreasing further to 0.46% by December 2022, possibly indicating challenges in capital utilization or profitability. By March 2023, the return on total capital turned negative at -0.65%, which could raise concerns about the company's ability to generate returns in relation to its total capital employed.
However, Supernus Pharmaceuticals Inc managed to reverse this negative trend by June 2024, achieving a return on total capital of 3.42%. The company's performance improved significantly in the following quarters, reaching 8.21% by December 2024.
Overall, Supernus Pharmaceuticals Inc's return on total capital has experienced fluctuations, suggesting varying levels of efficiency in utilizing its total capital resources during the period under review. Continuous monitoring and analysis of this ratio will be crucial for stakeholders to assess the company's financial health and performance.
Peer comparison
Dec 31, 2024